Search

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

The largest, most comprehensive study of its kind from Memorial Sloan Kettering Cancer Center finds that the biology of colorectal cancer in people under 50 is very similar to the disease in older people and more aggressive treatment of younger patients may not be warranted.

El estudio más grande y más completo de su tipo, realizado por el Memorial Sloan Kettering Cancer Center, concluye que la biología del cáncer colorrectal en personas menores de 50 años es muy similar a la de los pacientes de mayor edad, y que podría no estar justificado aplicar tratamientos más agresivos en los pacientes más jóvenes.

Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.

An enzyme that contributes to plaque formation in the brain also serves as a first line of defense against bacteria and viruses, suggesting a link between the two.

Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.

Cancer often leaves those it touches consumed with a feeling of hopelessness. But sometimes that feeling can motivate clinicians, patients, and supporters alike to turn soul-crushing moments into positive change.